Evidence map›Paper›PMID 27743385›Full record

ReviewEuropean journal of haematology2017

Vitamin D in hematological disorders and malignancies.

Paige M Kulling, Kristine C Olson, Thomas L Olson, David J Feith, Thomas P Loughran

Abstract readReview
In one paragraph

Review in European journal of haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Kinetics and concentrations of circulating 25-hydroxyvitamin D using different vitamin D repletion regimens.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Integrative Hematology: State of the Art.International journal of molecular sciences · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Paige M KullingUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, USA.
Kristine C OlsonUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, USA.
Thomas L OlsonUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, USA.
David J FeithUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0003-4981-1691
Thomas P LoughranUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, USA.
University of Virginia Cancer Center

Funding

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Genomic Architecture of LGL LeukemiaR01CA178393 · NCI · UNIVERSITY OF VIRGINIA · PI Thomas P. Loughran, Aakrosh Ratan · 2016 to 2026
$6.5M
Survival Mechanisms in Leukemic NK CellsR01CA098472 · NCI · UNIVERSITY OF VIRGINIA · PI LOUGHRAN, THOMAS P. · 2003 to 2016
$4.0M
NCI NIH HHS R01 CA098472NCI NIH HHS R01 CA178393NCI NIH HHS T32 CA009109NIAID NIH HHS T32 AI007496
6 · The paper itself

Abstract

Commonly known for its critical role in calcium homeostasis and bone mineralization, more recently vitamin D has been implicated in hematological cancer pathogenesis and shows promise as an anti-cancer therapy. Serum levels of 25(OH)D

Indexed as

AnimalsAntineoplastic AgentsDrug Resistance, NeoplasmDrug SynergismHematologic DiseasesHematologic NeoplasmsHumansImmune SystemJanus KinasesReceptors, CalcitriolSignal TransductionSTAT Transcription FactorsVitamin DAntineoplastic AgentsJanus KinasesReceptors, CalcitriolSTAT Transcription FactorsVitamin D25(OH)D3aplastic anemiacalcitriolimmune cellsleukemialymphomavitamin Dvitamin D receptor

Identifiers

PMID27743385
PMCPMC5303117
OpenAlexW2531724218

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.